Current trends in drug metabolism and pharmacokinetics.
10.1016/j.apsb.2019.10.001
- Author:
Yuhua LI
1
;
Qiang MENG
2
;
Mengbi YANG
3
;
Dongyang LIU
4
;
Xiangyu HOU
5
;
Lan TANG
6
;
Xin WANG
7
;
Yuanfeng LYU
3
;
Xiaoyan CHEN
5
;
Kexin LIU
2
;
Ai-Ming YU
8
;
Zhong ZUO
3
;
Huichang BI
1
Author Information
1. School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510275, China.
2. College of Pharmacy, Dalian Medical University, Dalian 116044, China.
3. School of Pharmacy, the Chinese University of Hong Kong, Hong Kong, China.
4. Drug Clinical Trial Center, Peking University Third Hospital, Beijing 100191, China.
5. Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
6. School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
7. School of Life Sciences, East China Normal University, Shanghai 200241, China.
8. UC Davis School of Medicine, Sacramento, CA 95817, USA.
- Publication Type:Journal Article
- Keywords:
Drug metabolism;
Drug–drug interactions;
Metabolizing enzymes;
Modeling;
Noncoding RNAs;
Nuclear receptors;
Pharmacokinetics;
Transporters
- From:
Acta Pharmaceutica Sinica B
2019;9(6):1113-1144
- CountryChina
- Language:English
-
Abstract:
Pharmacokinetics (PK) is the study of the absorption, distribution, metabolism, and excretion (ADME) processes of a drug. Understanding PK properties is essential for drug development and precision medication. In this review we provided an overview of recent research on PK with focus on the following aspects: (1) an update on drug-metabolizing enzymes and transporters in the determination of PK, as well as advances in xenobiotic receptors and noncoding RNAs (ncRNAs) in the modulation of PK, providing new understanding of the transcriptional and posttranscriptional regulatory mechanisms that result in inter-individual variations in pharmacotherapy; (2) current status and trends in assessing drug-drug interactions, especially interactions between drugs and herbs, between drugs and therapeutic biologics, and microbiota-mediated interactions; (3) advances in understanding the effects of diseases on PK, particularly changes in metabolizing enzymes and transporters with disease progression; (4) trends in mathematical modeling including physiologically-based PK modeling and novel animal models such as CRISPR/Cas9-based animal models for DMPK studies; (5) emerging non-classical xenobiotic metabolic pathways and the involvement of novel metabolic enzymes, especially non-P450s. Existing challenges and perspectives on future directions are discussed, and may stimulate the development of new research models, technologies, and strategies towards the development of better drugs and improved clinical practice.
